GENE ONLINE|News &
Opinion
Blog

AstraZenca
Trials & Approvals
Multifaceted Farxiga Shows Benefit in Chronic Kidney Disease
2020-07-30
Funding
AstraZeneca, Daiichi Sankyo Ink $6 Billion Deal for Lung and Breast Cancer Treatments
2020-07-28
COVID-19
COVID-19: AstraZeneca and University of Oxford’s Vaccine Candidate Shows Promise in Early Human Trials
2020-07-20
Trials & Approvals Pancreatic Cancer
Lynparza Notches EU Authorization for BRCA-Mutated Metastatic Pancreatic Cancer
2020-07-11
R&D RNA
AstraZeneca, Accent Ink $55M Partnership for Small Molecules Targeting RNA Modifying Proteins
2020-06-06
Trials & Approvals
ASCO 2020: AstraZeneca and Daiichi Sankyo’s Enhertu Impresses with Benefits in Lung, Stomach and Colorectal Cancer Trials
2020-06-05
R&D
ASCO 2020: AZ’s Tagrisso Promises Disease-Free Survival in Postoperative EGFR Mutation-Positive NSCLC
2020-05-30
Technology
What to Expect from the ASCO20 Virtual Program
2020-05-29
Trials & Approvals Prostate Cancer
Lynparza Greenlighted by FDA for HRR-Mutated, Metastatic Prostate Cancer
2020-05-27
COVID-19 Vaccine
COVID-19: AstraZeneca Receives $1B from BARDA to Develop Oxford’s Coronavirus Vaccine
2020-05-23
R&D
Spotlight: The Many Facets of AstraZeneca’s Farxiga
2020-05-15
Trials & Approvals Gastric Cancer
Enhertu, AstraZeneca’s Drug against Gastric Cancer Gets Breakthrough Therapy Designation
2020-05-14
R&D Lung Cancer
The Evolution of Lung Cancer Therapies at a Glance
2020-04-16
Trials & Approvals EGFR
Overwhelming Efficacy Allows AstraZeneca to End Cancer Drug Trial Sooner
2020-04-12
Licensing PARP Inhibitor
Japan Grants Orphan Drug Designation to Lynparza for Germline BRCA-mutated Pancreatic Cancer
2020-03-25
1 2 3 4 5
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
READ MORE
EVENT
SEE MORE
Newsletter

Subscribe to receive updates.

SIGN UP
Facebook
Youtube
Twitter
Linkedin
About
Explore
More
© 2024 GeneOnline
Privacy Policy | Terms of Service
Privacy Policy | Terms of Service
  • Subscribe to our newsletter and dive into the world of biopharma with us.
SIGN UP
x
Scroll to Top